

ASX/Media Release

16 May 2019

Botanix Provides Retraction in Presentation

Philadelphia PA Sydney Australia 16 May 2019: Medical dermatology company Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or the “Company”) refers to its press release dated 14 May 2019 in relation to the Company’s presentation at the Cannacord Genuity Cannabis Conference in New York (“Conference”).

Slide numbered 12 in the presented deck at the Conference presents a discussion on BTX 1801 intended for the treatment of skin infections. The box on the slide stating that “BTX 1801 may have the following benefits” included:

- Bacteria do not form resistance to BTX 1801

In relation to this statement, as investigations are still under way, Botanix does not consider, at this stage, that it has a reasonable basis for this statement and retracts it. As a consequence of this retraction Botanix advises that the retracted information should be disregarded and that accordingly investors should not rely on the retracted information for their investment decisions.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage medical dermatology company based in Perth, Australia and Philadelphia, PA. The Company’s focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of a widely studied natural compound. Treatment targets include inflammation, deterioration of the of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.

Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of Permetrex™ on both a fee-for-service and traditional license basis.

Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation. The patient treatment duration of clinical studies is generally completed within a 4 to 12-week timeframe.

The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical study in June 2018 with data read-out expected in Q3 2019. The BTX 1204 atopic dermatitis Phase 2 patient study is also underway with enrolment expected to be completed in 3Q CY2019. Finally, Phase 1b BTX 1308 psoriasis mechanism of action study is nearing completion with data anticipated to be available in 2Q CY2019. Pipeline projects that leverage the

anti-microbial properties of cannabidiol are also moving forward and are planned to enter the clinic in 2H 2019.

To learn more please visit: <https://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Matt Callahan
Botanix Pharmaceuticals
Founder & Executive Director
+1 215 767 4184
mcallahan@botanixpharma.com

Investor enquiries

Joel Seah
Vesparum Capital
P: +61 3 8582 4800
botanixpharma@vesparum.com

Media enquiries

Haley Chartres
Hales² Communications
P: +61 423 139 163
haley@h-squared.com.au